Skip to main content

Table 2 Median rate of measurement and probability of having a gap greater than 12 months between measurements of liver, renal or metabolic function

From: Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study

 

Liver (AST/ALT)

Renal (Creatinine)

Metabolic (Lipids)

 

Annual rate of testing, Median (IQR)

Subjects with ≥ 1 12-month gap

Annual rate of testing, Median (IQR)

Subjects with ≥ 1 12-month gap

Annual rate of testing, Median (IQR)

Subjects with ≥ 1 12-month gap

Overall

2.76 (1.60,3.73)

22 %

2.55 (1.44,3.38)

18 %

1.42 (0.50,2.52)

33 %

  First year of cART

3 (0, 4)

--

2 (0, 4)

--

1 (0, 3)

--

  Subsequent years

2.23 (0.31, 3.41)

--

1.78 (0, 3.06)

--

0.85 (0, 2.21)

--

Region

  British Columbia

3.25 (0.82,4.56)***

33 %***

1.66 (0.41,3.08)***

23 %***

1.05 (0.22,2.70)**

24 %***

  Ontario

2.53 (1.37,3.53)

17 %

2.35 (1.33,3.20)

14 %

1.45 (0.50,2.46)

32 %

  Quebec

2.88 (2.08,3.56)

21 %

2.88 (2.07,3.56)

17 %

1.48 (0.66,2.53)

38 %

Gender

  Male

2.80 (1.65,3.77)*

21 %***

2.59 (1.47,3.41)**

16 %**

1.49 (0.57,2.60)***

31 %***

  Female

2.60 (1.39,3.56)

29 %

2.33 (1.17,3.28)

24 %

1.02 (0.33,2.09)

43 %

Age

      

  <55

2.73 (1.57,3.71)*

23 %**

2.52 (1.43,3.36)**

18 %**

1.39 (0.49,2.48)**

34 %*

  ≥55

3.03 (1.92,4.10)

12 %

2.90 (1.83,3.69)

9 %

1.83 (0.79,2.95)

23 %

Race

  Caucasian

3.03 (1.43,4.16)***

24 %***

2.49 (1.07,3.44)***

21 %***

1.64 (0.53,2.85)***

31 %**

  Black

2.73 (1.55,3.74)

26 %

2.27 (1.23,3.17)

18 %

1.01 (0.43,2.09)

45 %

  Aboriginal

2.07 (0.51,3.59)

45 %

1.08 (0.28,2.54)

30 %

0.45 (0.12,1.95)

29 %

  Other

3.38 (2.39,4.40)

15 %

2.62 (1.72,3.49)

12 %

2.03 (0.75,2.98)

25 %

  Unknown

2.64 (1.67,3.43)

20 %

2.63 (1.70,3.39)

16 %

1.41 (0.52,2.34)

34 %

Risk Factor

  MSM

2.97 (1.98,3.92)***

18 %***

2.72 (1.81,3.48)***

15 %***

1.53 (0.61,2.61)***

32 %**

  Non-MSM

2.59 (1.26,3.68)

31 %

2.28 (0.97,3.32)

24 %

1.02 (0.31,2.02)

41 %

  IDU

2.13 (0.74,3.66)***

38 %***

1.46 (0.41,3.02)***

29 %***

0.66 (0.00,1.63)***

34 %

  Non-IDU

2.89 (1.87,3.84)

21 %

2.67 (1.79,3.48)

16 %

1.45 (0.59,2.52)

36 %

  Endemic

2.75 (1.83,3.62)

22 %

2.65 (1.87,3.44)

20 %

1.21 (0.57,2.12)

50 %***

  Non-Endemic

2.85 (1.63,3.86)

24 %

2.58 (1.42,3.43)

18 %

1.35 (0.46,2.46)

33 %

  Unknown Risk Factor

2.40 (1.35,3.34)***

15 %***

2.33 (1.34,3.19)**

14 %*

1.91 (0.67,2.91)***

21 %***

  Known Risk Factor

2.83 (1.69,3.81)

23 %

2.59 (1.46,3.43)

18 %

1.32 (0.48,2.41)

35 %

Year of cART Initiation

  >2005

2.77 (1.63,3.72)

12 %***

2.49 (1.21,3.40)*

9 %***

1.21 (0.33,2.30)***

23 %***

  2001-2005

2.77 (1.60,3.79)

27 %

2.61 (1.66,3.38)

22 %

1.66 (0.63,2.72)

40 %

  2000

2.53 (1.36,3.47)

53 %

2.51 (1.34,3.25)

37 %

1.45 (0.57,2.70)

49 %

Baseline CD4 count

  <200 cells/mm3

2.83 (1.62,3.78)***

25 %

2.55 (1.41,3.42)**

19 %

1.44 (0.56,2.59)***

34 %

  200-350 cells/mm3

2.79 (1.71,3.67)

18 %

2.61 (1.59,3.33)

15 %

1.39 (0.52,2.47)

31 %

  350-500 cells/mm3

2.66 (1.52,3.75)

21 %

2.50 (1.56,3.49)

17 %

1.48 (0.47,2.56)

31 %

  >500 cells/mm3

2.07 (0.82,3.31)

28 %

1.88 (0.00,3.09)

21 %

0.88 (0.00,2.09)

34 %

Baseline Regimen

  NNRTI-Based

2.68 (1.57,3.56)**

19 %***

2.45 (1.36,3.23)*

16 %**

1.30 (0.47,2.34)***

34 %***

  Boosted PI-Based

2.94 (1.59,4.01)

22 %

2.60 (1.40,3.52)

17 %

1.58 (0.54,2.73)

28 %

  PI-Based

2.66 (1.58,3.51)

30 %

2.62 (1.70,3.43)

24 %

1.31 (0.42,2.36)

41 %

  Other

2.95 (1.95,3.69)

18 %

2.89 (1.93,3.49)

15 %

1.97 (1.11,2.95)

40 %

Hepatitis C co-infection

  HCV+

2.38 (0.90,3.86)***

36 %***

1.82 (0.55,3.32)***

28 %***

0.88 (0.14,2.08)***

35 %

  HCV-

2.82 (1.77,3.73)

19 %

2.63 (1.67,3.39)

15 %

1.52 (0.60,2.60)

32 %

Hepatitis B co-infection

  HBV+

2.73 (1.49,3.45)

17 %

2.63 (1.51,3.30)

18 %

1.41 (0.59,2.37)

35 %

  HBV-

2.69 (1.74,3.55)

20 %

2.65 (1.80,3.43)

16 %

1.50 (0.59,2.50)

36 %

HCV and IDU status

  HCV- non-IDU

2.89 (1.89,3.79)***

20 %***

2.68 (1.81,3.45)***

16 %***

1.45 (0.60,2.49)***

36 %***

  HCV+ non-IDU

3.31 (2.02,4.54)

25 %

3.12 (1.76,4.29)

18 %

1.78 (0.70,3.18)

34 %

  HCV- IDU

2.90 (1.46,4.08)

23 %

2.30 (1.01,3.25)

15 %

1.21 (0.49,2.32)

23 %

  HCV+ IDU

1.83 (0.62,3.60)

42 %

1.34 (0.27,2.93)

33 %

0.52 (0.00,1.42)

37 %

  Unknown

2.45 (1.34,3.39)

17 %

2.34 (1.31,3.20)

16 %

1.75 (0.57,2.83)

24 %

  1. IDU injection drug use as risk factor for HIV acquisition, HCV+: positive for Hepatitis C; * = <0.01, ** = <0.001, *** = <0.0001